Trials / Recruiting
RecruitingNCT06884098
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-228B | AD-228B, 1Tab., Per Oral |
| DRUG | AD-2284 | AD-2284, 1Tab., Per Oral |
Timeline
- Start date
- 2025-03-10
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2025-03-19
- Last updated
- 2025-03-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06884098. Inclusion in this directory is not an endorsement.